NPM1 and acute myeloid leukemia: The authors demonstrated that secondary-type mutations were more frequent in patients with AML-MRC-H, compared to those with normal-karyotype NPM1-mutated AML (NK-AML), leading to inferior outcomes (OS and EFS).